The role of myeloid cells in the pathogenesis of MS is determined by the polarization they acquire after activation, and mediated by release of extracellular vesicles (MVs). We assessed the effects of treatments for MS on activation and polarization of myeloid cells. MVs levels and markers of polarization of myeloid cells have been assessed at baseline and up to 6 months after the start of a MS treatment. Patients had higher levels of MVs than controls, and these increased significantly over 6 months under natalizumab. Interferon β-1a significantly decreased M1 pro-inflammatory marker IL1β and upregulated Trem2, a receptor important for debris clearance; both interferon β-1a and fingolimod decreased pro-inflammatory marker IL6. Current treatments for MS significantly modulate myeloid cells activity.

Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients / Dalla Costa, Gloria; Finardi, Annamaria; Garzetti, Livia; Carandini, Tiziana; Comi, Giancarlo; Martinelli, Vittorio; Furlan, Roberto. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 39:2(2018), pp. 373-376. [10.1007/s10072-017-3176-2]

Disease-modifying treatments modulate myeloid cells in multiple sclerosis patients

Dalla Costa, Gloria;Comi, Giancarlo;Furlan, Roberto
2018-01-01

Abstract

The role of myeloid cells in the pathogenesis of MS is determined by the polarization they acquire after activation, and mediated by release of extracellular vesicles (MVs). We assessed the effects of treatments for MS on activation and polarization of myeloid cells. MVs levels and markers of polarization of myeloid cells have been assessed at baseline and up to 6 months after the start of a MS treatment. Patients had higher levels of MVs than controls, and these increased significantly over 6 months under natalizumab. Interferon β-1a significantly decreased M1 pro-inflammatory marker IL1β and upregulated Trem2, a receptor important for debris clearance; both interferon β-1a and fingolimod decreased pro-inflammatory marker IL6. Current treatments for MS significantly modulate myeloid cells activity.
2018
Disease modifying drugs; Extracellular vesicles; Interleukin-1β; Multiple sclerosis; Myeloid cells; Trem2; 2708; Neurology (clinical); Psychiatry and Mental Health
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/79295
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact